January 16, 2020
Gilead Sciences Inc., already facing political pressure and lawsuits over alleged anti-competitive behavior, was hit Wednesday with a proposed class action accusing the pharmaceutical giant of conspiring with other drugmakers to block the use of generics in HIV treatment regimens.